Bristol Myers gets priority review for first-line Reblozyl; Two startups clinch new cash
Bristol Myers Squibb is on the cusp of a new FDA decision. And it could come in the first-line setting.
The NJ-based Big Pharma said Monday that US regulators accepted a supplemental NDA for Reblozyl, also known as luspatercept, to treat anemia in adults with “very low- to intermediate-risk” myelodysplastic syndromes, who might need red blood cell transfusions. Patients must also not have previously received erythropoiesis-stimulating agents, or ESAs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
